Trial Profile
Safety Study of Cervarix in Females Aged 18-25 Years in Scotland
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Hepatitis A vaccine inactivated
- Indications Cervical cancer; Human papillomavirus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline Biologicals; GSK
- 24 Sep 2019 This trial has been discontinued in united kingdom
- 16 Apr 2009 New trial record